NCT05565781 (SMARTTHUNDER) is a NA clinical trial of ECG smartwatch in Paroxysmal Atrial Fibrillation, sponsored by Hospital Universitari Vall d'Hebron Research Institute.

Who is sponsoring NCT05565781?

NCT05565781 is sponsored by Hospital Universitari Vall d'Hebron Research Institute.

What drugs are being tested in NCT05565781?

Interventions in NCT05565781: ECG smartwatch, Insertable Cardiac Monitor (ICM), External ECG Monitoring.

What condition does NCT05565781 study?

NCT05565781 studies Paroxysmal Atrial Fibrillation, Cryptogenic Stroke.

Is NCT05565781 still recruiting?

NCT05565781 is currently recruiting now. Last updated 4 April 2025.

Last reviewed 2025-04-04 · How we verify

NCT05565781: SMARTTHUNDER

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Smartwatch and External Holter Monitoring to Detect Atrial Fibrillation in Patients With Cryptogenic Stroke

Recruiting now NA Last updated 4 April 2025

What this trial tests

NA trial testing ECG smartwatch in Paroxysmal Atrial Fibrillation in 100 participants. Currently enrolling.

Timeline

28 March 2022

Primary endpoint
1 June 2025

1 September 2026

Quick facts

Lead sponsor	Hospital Universitari Vall d'Hebron Research Institute
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	screening
Enrollment	100
Start date	28 March 2022
Primary completion	1 June 2025
Estimated completion	1 September 2026
Sites	1 location across Spain

Drugs / interventions tested

ECG smartwatch
Insertable Cardiac Monitor (ICM)
External ECG Monitoring

Conditions studied

Paroxysmal Atrial Fibrillation — all drugs for Paroxysmal Atrial Fibrillation →
Cryptogenic Stroke — all drugs for Cryptogenic Stroke →

Sponsor

Hospital Universitari Vall d'Hebron Research Institute

Who can join

55 and older, any sex, with Paroxysmal Atrial Fibrillation or Cryptogenic Stroke. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Stroke recurrence largely depends on the detection of the cause and the control of vascular risk factors, with occult atrial fibrillation (AF) being one of the most important. Prolonged ambulatory cardiac monitoring is recommended for detecting occult AF. Currently, there are non-invasive monitoring devices such as the textile Holter that have proven to be useful for monitoring for up to 30 days but not longer. Another alternative is smartwatches, although they must be validated for use in the elderly population who have had a stroke.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Atrial fibrillation: epidemiology, screening and digital health.
Linz D, Gawalko M, Betz K, Hendriks JM, et al · · 2024 · cited 230× · PMID 38362546 · DOI 10.1016/j.lanepe.2023.100786
Accuracy of a Smartwatch to Assess Heart Rate Monitoring and Atrial Fibrillation in Stroke Patients.
Meza C, Juega J, Francisco J, Santos A, et al · · 2023 · cited 8× · PMID 37430546 · DOI 10.3390/s23104632
11th European Stroke Organisation Conference Abstracts - 21-23 May 2025, Helsinki, Finland.
· 2025 · cited 3× · PMID 40726475 · DOI 10.1177/23969873251329993

Verify or expand the search:

Other recruiting trials for Paroxysmal Atrial Fibrillation

Currently open trials in the same condition.

NCT07535268 — REPRESENT-PF Registry · recruiting
NCT07344961 — Determinates of Atrial Tracking and Prevalence of Atrial Fibrillation in the Micra AV2 (DANCE AFIB) · recruiting
NCT07281898 — Burst Stimulation for Paroxysmal Atrial Fibrillation · NA · recruiting
NCT07116525 — A Study Assessing Arrhythmia Mapping With a Multi-Electrode Mapping Catheter · NA · recruiting
NCT06765356 — Pragmatic Evaluation of a Pentaspline Pulsed Field Ablation System to Treat Atrial Fibrillation and Related Arrhythmias · Phase 4 · active not recruiting

Other Hospital Universitari Vall d'Hebron Research Institute trials

Trials by the same sponsor.

NCT07519343 — Migraine and Endometriosis: The FEMININE Study · not yet recruiting
NCT07509541 — Hemodynamic and Respiratory Instability During Percutaneous Pulmonary Thrombectomy · not yet recruiting
NCT07456280 — Evaluation of the Non-invasive Electrocardiographic Monitoring Strategy Associated With Early Discharge in Patients With · NA · not yet recruiting
NCT07281911 — Early Biological and Mechanical Profiling in Sepsis-Associated ARDS · not yet recruiting
NCT07430501 — Using Digital Twin Technology and Clinical Decision Support Systems to Improve the Early Detection, Personalised Treatme · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05565781 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hospital Universitari Vall d'Hebron Research Institute
Last refreshed: 4 April 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05565781.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing